Nanotargeted agents: an emerging therapeutic strategy for breast cancer.
Breast cancer is the most common female cancer worldwide and represents 12% of all cancer cases. Improvements in survival rates are largely attributed to improved screening and diagnosis. Conventional chemotherapy remains an important treatment option but it is beset with poor cell selectivity, serious side effects and resistance. Nanoparticle drug delivery systems bring promising opportunities to breast cancer treatment. They may improve chemotherapy by targeting drugs to tumors, generating high drug concentrations at tumors providing slow release of the drug, increased drug stability and concomitant reductions in side effects. The nanotechnology-based drug delivery approaches and the current research and application status of nano-targeted agents for breast cancer are discussed in this review to provide a basis for further study on targeted drug delivery systems.
['Du|Manling|M|', 'Ouyang|Yong|Y|', 'Meng|Fansu|F|', 'Ma|Qianqian|Q|', 'Liu|Hui|H|', 'Zhuang|Yong|Y|', 'Pang|Mujuan|M|', 'Cai|Tiange|T|', 'Cai|Yu|Y|']
D000818:Animals D000970:Antineoplastic Agents D001943:Breast Neoplasms D004337:Drug Carriers D016503:Drug Delivery Systems D005260:Female D006801:Humans D050997:Nanomedicine D053758:Nanoparticles D036103:Nanotechnology
breast cancer nano-targeted agents active targeting passive targeting physical and chemical targeting